Strategic partnerships Recent alliance with Remergify, Inc. and planned collaboration with Farrington Capital Group signals a path to accelerated development and global commercialization of near-infrared medical technology, presenting a sales entry point through integrated channel partners and fundraising-backed expansion.

Product pipeline Current Vein-Eye handheld and hospital cart offerings with FDA registration and CE marking indicate ready-to-sell products in clinical environments, plus an upcoming PAT 2700 brain hemorrhage scanner that can open additional markets in emergency, ER, battlefield, and ambulance settings.

Target markets Solutions addressing venous visualization, brain injury detection, and brain disease monitoring align with hospitals, surgical centers, trauma centers, and military medical facilities, suggesting cross-sell opportunities to nephrology imaging, neurology departments, and critical care units.

Decision maker access Given the operational readiness and clinical utility of Vein-Eye, engage procurement, radiology, anesthesiology, neurosurgery, and trauma directors, as well as potential distributors and group purchasing organizations seeking innovative imaging technologies.

Financial readiness Funding level under $1M with a $1.2M investment and a demonstrated go-to-market strategy via strategic alliances highlight an opportunity to position NII for joint ventures, co-development deals, and bundled offerings with larger medtech players that have sales and distribution footprints.